文献速递肝病

机制与分子:原发性胆汁性胆管炎的治疗靶点是什么?

Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
PubMed 文献 · Hepatology · 2022-03-10

本文综述原发性胆汁性胆管炎(PBC)的潜在治疗靶点及在研药物。熊去氧胆酸(UDCA)治疗PBC并非总能充分阻止进展至肝失代偿和/或需肝移植;奥贝胆酸辅助治疗可在部分患者中提供进一步生化改善,但明显瘙痒或晚期肝硬化患者耐受不佳。靶点 broadly 分为改变胆汁、炎症、细胞存活或纤维化四类,法尼醇X受体(FXR)和过氧化物酶体增殖物激活受体(PPAR)因调控多条通路而成为热门靶点。

要点

  • UDCA治疗PBC并非总能充分阻止进展至肝失代偿和/或需肝移植。
  • 奥贝胆酸辅助治疗可在部分患者中提供进一步生化改善,但明显瘙痒或晚期肝硬化患者耐受不佳。
  • 在研靶点分为改变胆汁、炎症、细胞存活或纤维化四类,FXR和PPAR因调控多条通路而受关注。

核心结论

  • UDCA治疗PBC并非总能充分阻止进展至肝失代偿和/或需肝移植,因此识别新的治疗靶点很重要。
  • 奥贝胆酸辅助治疗可在部分患者中提供进一步生化改善,但明显瘙痒或晚期肝硬化患者耐受不佳。

研究设计与样本

  • 本文为综述,讨论PBC的主要潜在治疗靶点并举例介绍目前正在研发的若干具体药物。

主要发现

  • 靶点 broadly 分为改变胆汁、炎症、细胞存活或纤维化四类。
  • 在胆汁方面,缩小胆汁酸池大小或通过使胆汁更亲水或富含磷脂酰胆碱来改善胆汁质量,可能减轻胆汁淤积性损伤。
  • 通过加固碳酸氢盐伞或改善细胞膜完整性,可能延长胆管上皮细胞存活。
  • 自身免疫和胆管炎有可能通过调节免疫系统得到改善,靶向细胞因子、免疫检查点和抗线粒体抗体是更聚焦的免疫抑制策略示例。
  • 干细胞治疗和抑制淋巴细胞转运是更新颖的广泛免疫调节方法,抗纤维化治疗也可能有助于预防PBC进展。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) is not always sufficient to prevent progression to hepatic decompensation and/or need for liver transplant. Adjuvant therapy with obeticholic acid may provide additional biochemical improvements in some patients, but it is not well-tolerated by patients with significant itch or advanced cirrhosis. Thus, new and creative approaches to treating patients with PBC are important to identify. This review discusses major potential therapeutic targets in PBC and provides examples of some specific agents currently in development for the treatment of PBC. Targets are broadly classified into those which strive to modify bile, inflammation, cell survival, or fibrosis. In bile, shrinking the size of the bile acid pool or modifying the quality of the bile by making it more hydrophilic or enriched in phosphatidylcholine may ameliorate cholestatic injury. Biliary epithelial cell survival may be extended by fortifying the bicarbonate umbrella or improving cell membrane integrity. Autoimmunity and cholangitis have the potential to be improved via regulation of the immune system. Targeting cytokines, immune checkpoints, and anti-mitochondrial antibodies are examples of a more focused immunosuppression approach. Stem cell therapy and lymphocyte trafficking inhibition are more novel methods of broad immune regulation. Anti-fibrotic therapies are also potentially useful for preventing progression of PBC. The nuclear hormone receptors, farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) regulate many of these pathways: cholestasis, inflammation, and fibrosis, which is why they are being enthusiastically pursued as potential therapeutic targets in PBC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mayo MJ. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis? Hepatology. 2022. PMID: 35152430. doi:10.1002/hep.32405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。